Corient Private Wealth LLC Has $1.23 Million Stake in Ralliant Corporation $RAL

Corient Private Wealth LLC raised its holdings in Ralliant Corporation (NYSE:RAL) by 58.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,191 shares of the company’s stock after buying an additional 8,922 shares during the period. Corient Private Wealth LLC’s holdings in Ralliant were worth $1,232,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RAL. Phocas Financial Corp. boosted its stake in Ralliant by 81.2% in the 4th quarter. Phocas Financial Corp. now owns 157,116 shares of the company’s stock valued at $7,999,000 after purchasing an additional 70,403 shares during the period. Victory Capital Management Inc. increased its position in Ralliant by 1,726.7% during the 3rd quarter. Victory Capital Management Inc. now owns 873,794 shares of the company’s stock worth $38,211,000 after buying an additional 825,960 shares during the period. Teacher Retirement System of Texas lifted its holdings in shares of Ralliant by 6.9% during the fourth quarter. Teacher Retirement System of Texas now owns 570,878 shares of the company’s stock worth $29,063,000 after buying an additional 36,800 shares in the last quarter. Hudson Bay Capital Management LP lifted its holdings in shares of Ralliant by 278.8% during the third quarter. Hudson Bay Capital Management LP now owns 179,891 shares of the company’s stock worth $7,867,000 after buying an additional 132,403 shares in the last quarter. Finally, Gabelli Funds LLC bought a new stake in shares of Ralliant in the third quarter valued at about $1,166,000.

Ralliant Stock Performance

Shares of Ralliant stock opened at $71.93 on Thursday. The company has a 50 day moving average of $59.71 and a 200-day moving average of $51.69. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $75.41. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. The company has a market cap of $8.05 billion and a PE ratio of -6.57.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.08. The business had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business’s quarterly revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities research analysts forecast that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s payout ratio is presently -1.83%.

Wall Street Analysts Forecast Growth

RAL has been the topic of a number of recent research reports. Evercore initiated coverage on shares of Ralliant in a research report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price target on the stock. Oppenheimer boosted their price objective on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a report on Wednesday, May 27th. Finally, Barclays boosted their price target on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $69.00.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.